Lunit's Insight MMG device has completed stage II of Australia's national breast cancer screening project.
The initiative, called the BreastScreen NSW (BSNSW) Machine Reading Solution Project, aims to improve the survival rates of women with breast cancer by finding the cancer earlier.
Stage I included 650,000 mammograms and validated Lunit Insight MMG's accuracy and clinical benefits. Stage II will seek to validate Lunit Insight MMG's production workflow and will include 200,000 exams assessed over six months. This second stage will also include an evaluation of Lunit's Insight DBT device.
Once stage II is completed successfully, the company will advance to stage III, which will integrate Lunit Insight MMG into BreastScreen NSW's PACS; after all stages are concluded, Lunit will ink a five-year contract with BreastScreen NSW, it said.
